Category IV indications for therapeutic apheresis: ASFA fourth special issue
Authors
Shaz, Beth H.Linenberger, Michael L.
Bandarenko, Nicholas
Winters, Jeffrey L.
Kim, Haewon C.
Marques, Marisa B.
Sarode, Ravindra
Schwartz, Joseph
Weinstein, Robert
Wirk, Ashka
Szczepiorkowski, Zbigniew M.
UMass Chan Affiliations
Department of Medicine, Division of Transfusion MedicineDocument Type
Journal ArticlePublication Date
2007-03-23Keywords
*Blood Component RemovalDisease
Humans
Practice Guidelines as Topic
Societies, Medical
United States
Hemic and Immune Systems
Other Medical Specialties
Metadata
Show full item recordAbstract
The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.Source
J Clin Apher. 2007 Jun;22(3):176-80. Link to article on publisher's siteDOI
10.1002/jca.20131Permanent Link to this Item
http://hdl.handle.net/20.500.14038/50106PubMed ID
17377982Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1002/jca.20131